fludarabine has been researched along with Neoplasms in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.17) | 18.7374 |
| 1990's | 4 (8.33) | 18.2507 |
| 2000's | 25 (52.08) | 29.6817 |
| 2010's | 14 (29.17) | 24.3611 |
| 2020's | 3 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Almazi, JG; Alomari, M; Belov, L; Best, OG; Christopherson, RI; Graham, ME; Mulligan, SP; Shen, Y | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I | 1 |
| Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY | 1 |
| Austin, E; Burt, DJ; Byatte, AJ; Chester, KA; Gilham, DE; Guest, RD; Halford, SER; Hawkins, RE; Kirillova, N; Nabarro, S; Pillai, M; Rothwell, DG; Sharma, SK; Thistlethwaite, FC; Valle, JW; Wan, S; Westwood, NB | 1 |
| Schmidt, C | 1 |
| Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G | 1 |
| Nishikawa, H | 1 |
| Allan, PW; Carroll, WR; Chung, TK; Clemons, L; Conry, RM; Hong, J; Hunt, FR; Lowman, D; Mannion, K; Nabell, L; Parker, WB; Richman, J; Rosenthal, EL; Sorscher, EJ | 1 |
| Choi, ES; Im, HJ; Jang, S; Koh, KN; Kwon, SW; Lee, SW; Park, CJ; Seo, JJ; Suh, JK | 1 |
| Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M | 1 |
| van der Griend, R; van der Spek, E | 1 |
| Atkinson, K; Burns, AM; Hart, DN; Kambouris, ME; Lange, J; Lourie, R; Munster, DJ; Rice, AM; Sinfield, L; Turner, BE | 1 |
| Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Costello, R; Csako, G; Langan, RC; Prieto, PA; Rosenberg, SA; Sherry, RM; White, DE; Wunderlich, J; Yang, JC; Zlott, D | 1 |
| Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C | 1 |
| Dallas, MH; Hartford, C; Laver, J; Leung, W; Pillai, A; Shook, DR; Srinivasan, A; Triplett, BM | 1 |
| Blaise, D; Castagna, L | 1 |
| Diker-Cohen, T; Lahav, M; Natur, A; Shapira, H; Szyper-Kravitz, M; Uziel, O | 1 |
| Bos, GM; Huugen, D; Jansen, M; Jansen, R; Lalisang, R; Schouten, HC; Wagstaff, J | 1 |
| Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ | 1 |
| Balzarotti, M; Bertuzzi, A; Castagna, L; Farè, M; Grimoldi, MG; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F | 1 |
| Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I | 1 |
| Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K | 1 |
| Barrett, AJ; Childs, R; Donohue, T; Espinoza-Delgado, I; Geller, N; Gorak, E; Srinivasan, R; Suffredini, A | 1 |
| Abidi, MH; Alangaden, G; Chandrasekar, PH; Heilbrun, LK; Klein, JL; Mellon-Reppen, S; Narreddy, S; Peres, E; Smith, D | 1 |
| Bertetto, O; Busca, A; de Fabritiis, P; Falda, M; Locatelli, F; Novarino, A; Picardi, A; Zeuli, M | 1 |
| Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP | 1 |
| Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
| Ding, W; Meng, H; Ni, W; Qian, W; Yang, C; Yang, X | 1 |
| Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Geenen, V; Gothot, A; Herens, C; Meuris, N; Schaaf-Lafontaine, N; Seidel, L; Vanbellighen, JF; Willems, E | 1 |
| Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD | 1 |
| Faulds, D; McTavish, D; Ross, SR | 1 |
| Estey, E; Gandhi, V; Gregoire, V; Huang, P; Keating, MJ; Plunkett, W; Robertson, LE; Yang, LY | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C | 1 |
| Vastag, B | 1 |
| Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E | 1 |
| Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C | 1 |
| Sallah, S; Wan, JY | 1 |
| Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A | 1 |
| Grever, MR; Malspeis, L; Staubus, AE; Young, D | 1 |
| Finley, RS; Hood, MA | 1 |
| Hutton, JJ; Von Hoff, DD | 1 |
8 review(s) available for fludarabine and Neoplasms
| Article | Year |
|---|---|
[Regulatory T cells in cancer immunotherapy].
Topics: Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Cyclophosphamide; Humans; Immune Tolerance; Immunosuppressive Agents; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasms; Programmed Cell Death 1 Receptor; Receptors, CCR4; T-Lymphocytes, Regulatory; Vidarabine | 2014 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
Do different conditioning regimens really make a difference?
Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Neoplasms, Experimental; Vidarabine | 1993 |
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Neoplasms; Vidarabine | 1993 |
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine | 2001 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Fludarabine: a review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Neoplasms; Remission Induction; Vidarabine | 1991 |
9 trial(s) available for fludarabine and Neoplasms
| Article | Year |
|---|---|
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.
Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pharmaceutical Preparations; Prospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Topics: Abdominal Pain; Adult; Aged; Anemia; Carcinoembryonic Antigen; Cohort Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-6; Lung; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Treatment Outcome; Vidarabine; Vomiting | 2017 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2014 |
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
Topics: Adenoviridae; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Escherichia coli; Female; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Purine-Nucleoside Phosphorylase; Tumor Cells, Cultured; Vidarabine | 2015 |
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
Topics: Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myelopoiesis; Neoplasms; Neutrophils; Risk Factors; Sex Factors; Syndrome; Transplantation Conditioning; Vidarabine | 2005 |
Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Topics: Adult; Aged; Anesthesia Recovery Period; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Flow Cytometry; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms; Peripheral Blood Stem Cell Transplantation; Receptors, Antigen, T-Cell, alpha-beta; Thymus Gland; Time Factors; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2008 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
31 other study(ies) available for fludarabine and Neoplasms
| Article | Year |
|---|---|
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclophosphamide; Humans; Neoplasms; Nucleosides; Tumor Suppressor Protein p53; Vidarabine | 2022 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2017 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Infant; Lymphocyte Depletion; Male; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2017 |
Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
Topics: Aged; Antineoplastic Agents; Databases, Factual; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Neoplasms, Second Primary; Research Design; Sex Factors; Time Factors; Treatment Outcome; Vidarabine | 2008 |
Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Injections, Intraperitoneal; Kinetics; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follicle Stimulating Hormone; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasms; Ovary; Primary Ovarian Insufficiency; Radiotherapy; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2011 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2013 |
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Fluorouracil; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotype; Male; Middle Aged; Neoplasms; Telomere; Vidarabine | 2013 |
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
Topics: Adult; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2002 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Topics: Academies and Institutes; Antineoplastic Agents; Aspergillosis; Cyclophosphamide; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Michigan; Middle Aged; Myeloablative Agonists; Neoplasms; Opportunistic Infections; Retrospective Studies; Review Literature as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Renal Cell; Colonic Neoplasms; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Rectal Neoplasms; Sarcoma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |
Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms; Vidarabine | 2007 |
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate | 1984 |
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2000 |
A brief history of the brief history of low-dose transplants.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; History, 20th Century; Humans; Immunosuppressive Agents; Neoplasms; United States; Vidarabine | 2000 |
Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.
Topics: Adult; Autoantibodies; Factor VIII; Female; Hemorrhagic Disorders; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Partial Thromboplastin Time; Vidarabine | 2001 |
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate | 1990 |
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
Topics: Cell Survival; Cells, Cultured; Cladribine; Colony-Forming Units Assay; Deoxyadenosines; Drug Evaluation, Preclinical; Female; Humans; Kinetics; Neoplasms; Vidarabine | 1986 |